Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mainz Biomed N.V. (MYNZ)

Mainz Biomed N.V. (MYNZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,189
  • Shares Outstanding, K 12,010
  • Annual Sales, $ 900 K
  • Annual Income, $ -26,300 K
  • 60-Month Beta 0.28
  • Price/Sales 13.88
  • Price/Cash Flow N/A
  • Price/Book 3.25
Trade MYNZ with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.64
  • Most Recent Earnings $-0.24 on 04/09/24
  • Latest Earnings Date 05/21/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.31
  • Number of Estimates 1
  • High Estimate -0.31
  • Low Estimate -0.31
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +31.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7352 +3.39%
on 05/01/24
1.1300 -32.73%
on 04/09/24
-0.3199 (-29.62%)
since 04/03/24
3-Month
0.7352 +3.39%
on 05/01/24
1.2200 -37.70%
on 02/09/24
-0.1149 (-13.13%)
since 02/02/24
52-Week
0.7352 +3.39%
on 05/01/24
6.0000 -87.33%
on 06/02/23
-4.7099 (-86.10%)
since 05/03/23

Most Recent Stories

More News
Mainz Biomed Expands Commercial Footprint into Poland

Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today

MYNZ : 0.7710 (+0.77%)
Being Overweight or Obese Increases Risk of Developing Colorectal Cancer

Maintaining a healthy weight is important for general health, but growing evidence reveals obesity’s role in the development of chronic illnesses and even deadly cancers. Obesity is one of the most frequent...

MYNZ : 0.7710 (+0.77%)
BioNTech’s mRNA Vaccine Shows Early Potential Against Pancreatic Cancer

One of the most stubborn, deadly cancers is pancreatic cancer. What if individualized mRNA vaccinations could support the immune system’s defense? One of the deadliest forms of cancer around, pancreatic...

MYNZ : 0.7710 (+0.77%)
A New Groundbreaking Tool to Detect Colon Cancer Earlier

A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This discovery...

MYNZ : 0.7710 (+0.77%)
EXAS : 62.19 (+2.73%)
GH : 19.08 (+2.69%)
VCYT : 20.63 (+2.18%)
HOLX : 76.38 (+0.62%)
Colon Cancer Creeping Into Younger Adults – New R&D Uncovers Early Signs

Spots of blood after bowel movements, stomach aches, and protracted episodes of diarrhea may be symptoms of early-onset colorectal cancer, which is increasingly diagnosed in young adults who are ineligible...

MYNZ : 0.7710 (+0.77%)
AI Tool Predicts Colon Cancer Survivorship and Response to Treatment

Harvard Medical School and National Cheng Kung University in Taiwan have designed an artificial intelligence (AI) algorithm to improve colorectal cancer prognosis and treatment options. The new technique...

MYNZ : 0.7710 (+0.77%)
New Artificial Intelligence Tool Can Diagnose Colon Cancer

A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and deciding...

MYNZ : 0.7710 (+0.77%)
EXAS : 62.19 (+2.73%)
GH : 19.08 (+2.69%)
VCYT : 20.63 (+2.18%)
BHC.TO : 11.11 (+0.54%)
BHC : 8.10 (+0.12%)
Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development

Dr. Frank Krieg-Schneider to lead development across Mainz Biomed’s portfolio of advanced cancer detection products including its flagship product...

MYNZ : 0.7710 (+0.77%)
Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board

Renowned Experts to Support ColoAlert’s U.S. Pivotal Clinical Trial and Development of Additional Cancer DiagnosticsDr. Wang is the GI (Gastrointestinal)...

MYNZ : 0.7710 (+0.77%)
Mainz Biomed Today to Provide Corporate Update for First Half of 2022

Company to Host Webcast Today - July 12th - at 4.00pm ET...

MYNZ : 0.7710 (+0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Mainz Biomed N.V. develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. Mainz Biomed N.V. is based in BERKELEY, Calif....

See More

Key Turning Points

3rd Resistance Point 0.8671
2nd Resistance Point 0.8410
1st Resistance Point 0.8031
Last Price 0.7710
1st Support Level 0.7391
2nd Support Level 0.7130
3rd Support Level 0.6751

See More

52-Week High 6.0000
Fibonacci 61.8% 3.9888
Fibonacci 50% 3.3676
Fibonacci 38.2% 2.7464
Last Price 0.7710
52-Week Low 0.7352

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar